Stein B, Schmitz W, Scholz H, Seeland C
Abteilung Allgemeine Pharmakologie, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany.
J Mol Cell Cardiol. 1994 Mar;26(3):403-14. doi: 10.1006/jmcc.1994.1049.
The aim of the present study was to elucidate the question of whether cardiomyocytes possess stimulatory adenylyl cyclase-coupled A2-adenosine receptors and whether these receptors modify contractility. In isolated electrically driven ventricular cardiomyocytes from guinea-pig hearts the effects of the A2-adenosine receptor agonist 2-[(p-2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamide-adenos ine (CGS 21680C) alone and in the presence of isoprenaline on cAMP content and contractile response were investigated. In addition, we characterized these effects with selective A1- and A2-adenosine receptor antagonists [1,3-dipropyl-8-cyclopentylxanthine, DPCPX and 9-chloro-2-(2-furanyl)-5,6-dihydro-1,2,4-triazolo-(1,5-c)quinazolin++ +-5-imine, CGS 15943A, respectively]. To investigate the signal transduction pathway, the influence of pertussis toxin, known to inhibit signal transducing GTP-binding proteins (Gi/o-proteins), on these effects was studied. CGS 21680C alone and in the presence of isoprenaline increased cAMP content concentration-dependently (0.1 nmol/l-10 mumol/l) to maximally 154% of control and 137% of isoprenaline value, respectively. In the presence of the A1-adenosine receptor antagonist DPCPX (0.3 mumol/l) or after pertussis toxin-pretreatment (18 micrograms/kg i.v. 24-26 h) the cAMP increase was further elevated. The A2-adenosine receptor antagonist CGS 15943A (0.01 mumol/l) abolished these effects, indicating that these effects are mediated by A2-adenosine receptors. The elevation in cAMP content was not accompanied by an increase in contractile response. However, in the presence of isoprenaline CGS 21680C reduced contractile response to 62% of the isoprenaline value. The A1-adenosine receptor antagonist DPCPX abolished the decrease in contractility, whereas the A2-adenosine receptor antagonist CGS 15943A did not effect contractility. Thus the reduction in contractility is mediated via cAMP-decreasing A1-adenosine receptors. The results provide evidence for the coexistence of cAMP-reducing A1- and cAMP-elevating A2-adenosine receptors on ventricular cardiomyocytes. Only stimulation of A1-adenosine receptors leads to a subsequent reduction in contractile response, whereas A2-adenosine receptors do not affect contractility.
本研究的目的是阐明心肌细胞是否拥有与刺激性腺苷酸环化酶偶联的A2 - 腺苷受体,以及这些受体是否会改变收缩性。在豚鼠心脏分离的电驱动心室肌细胞中,研究了A2 - 腺苷受体激动剂2 - [(对 - 2 - 羧乙基) - 苯乙氨基] - 5'-N - 乙基羧酰胺 - 腺苷(CGS 21680C)单独以及在异丙肾上腺素存在时对环磷酸腺苷(cAMP)含量和收缩反应的影响。此外,我们用选择性A1 - 和A2 - 腺苷受体拮抗剂[分别为1,3 - 二丙基 - 8 - 环戊基黄嘌呤,DPCPX和9 - 氯 - 2 - (2 - 呋喃基) - 5,6 - 二氢 - 1,2,4 - 三唑并(1,5 - c)喹唑啉 - 5 - 亚胺,CGS 15943A]对这些作用进行了表征。为了研究信号转导途径,研究了已知可抑制信号转导GTP结合蛋白(Gi / o蛋白)的百日咳毒素对这些作用的影响。单独的CGS 21680C以及在异丙肾上腺素存在时均浓度依赖性地增加cAMP含量(0.1 nmol / l - 10 μmol / l),分别最大达到对照值的154%和异丙肾上腺素值的137%。在A1 - 腺苷受体拮抗剂DPCPX(0.3 μmol / l)存在下或经过百日咳毒素预处理(静脉注射18 μg / kg,24 - 26小时)后,cAMP的增加进一步升高。A2 - 腺苷受体拮抗剂CGS 15943A(0.01 μmol / l)消除了这些作用,表明这些作用是由A2 - 腺苷受体介导的。cAMP含量的升高并未伴随着收缩反应的增加。然而,在异丙肾上腺素存在时,CGS 21680C将收缩反应降低至异丙肾上腺素值的62%。A1 - 腺苷受体拮抗剂DPCPX消除了收缩性的降低,而A2 - 腺苷受体拮抗剂CGS 15943A对收缩性没有影响。因此,收缩性的降低是通过降低cAMP的A1 - 腺苷受体介导的。结果为心室肌细胞上降低cAMP的A1 - 腺苷受体和升高cAMP的A2 - 腺苷受体的共存提供了证据。仅刺激A1 - 腺苷受体导致随后收缩反应的降低,而A2 - 腺苷受体不影响收缩性。